| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Targocil targets the wall teichoic acid (WTA) biosynthesis pathway in Gram-positive bacteria. WTA is an essential component of the cell wall in S. aureus and other Gram-positive organisms. By inhibiting WTA biosynthesis, Targocil disrupts cell wall integrity, leading to bacterial growth inhibition. Its activity against both MSSA and MRSA makes it a promising candidate for treating drug-resistant staphylococcal infections.
|
|---|---|
| ln Vitro |
The MIC for Targocil in relation to S. Newman, MW2, MG2375, and MG2389 strains of aureus had a concentration of 1 μg/mL. Targocil exhibited outstanding performance in dealing with S. MSSA and MRSA isolates with MICs ranging from 1 to 2 μg/mL were among the aureus isolates from probable instances of bacterial keratitis. Derived from 1835F03, tartagocil has superior efficacy against all isolates of keratitis when compared to the original lead chemical, 1835F03. Bovine serum was found to exhibit a discernible mild reduction of 1835F03 and Targocil's in vitro antibacterial activity, resulting in a 4- to 8-fold increase in their respective MICs. Even after 24 hours of exposure, HCEC found targocil at 5 μg/mL to be only somewhat harmful when compared to the vehicle alone. Nevertheless, at every investigated time point, 40 μg/mL targrocil was hazardous. When HCEC was present, Targocil quickly stopped Newman and MG2375 from growing in vitro at 10×MIC [1].
In vitro, Targocil shows excellent activity against S. aureus isolates from suspected cases of bacterial keratitis, including both MSSA and MRSA isolates, with MICs ranging from 1 to 2 μg/mL. MICs against S. aureus strains Newman, MW2, MG2375, and MG2389 are 1 μg/mL for all strains. Bovine serum has a moderate inhibitory effect on its antimicrobial activity, increasing MICs by 4- to 8-fold. At 5 μg/mL, Targocil exhibits little toxicity for human corneal epithelial cells (HCECs), even after 24 hours of exposure. |
| ln Vivo |
In vivo efficacy data for Targocil is not extensively detailed in the search results. Its potential as a therapeutic agent for bacterial infections is supported by its potent in vitro activity against clinically relevant isolates, including MRSA. The compound's ability to inhibit WTA biosynthesis makes it a promising candidate for further in vivo evaluation in animal models of staphylococcal infection.
|
| Enzyme Assay |
In vitro enzyme assays for Targocil typically involve measuring its inhibition of wall teichoic acid biosynthesis using biochemical methods. The compound's activity can be assessed by measuring the incorporation of radiolabeled precursors into WTA or by quantifying WTA levels using specific assays. Its antibacterial activity is evaluated using standard broth microdilution assays to determine the MIC against various S. aureus strains.
|
| Cell Assay |
In vitro cell-based assays for Targocil involve treating bacterial cultures with the compound to assess its antibacterial activity. MICs are determined using broth microdilution or agar dilution methods against a panel of S. aureus strains, including MSSA and MRSA. Cytotoxicity against mammalian cells, such as human corneal epithelial cells, is assessed using standard cell viability assays. The compound's effects on WTA biosynthesis can be studied in bacterial cell cultures.
|
| Animal Protocol |
In vivo animal experiments for Targocil have not been extensively reported. Its potential for treating bacterial infections would be evaluated in animal models of S. aureus infection, such as a murine wound infection model or a systemic infection model. Efficacy endpoints would include bacterial burden reduction and survival rates.
|
| ADME/Pharmacokinetics |
Targocil has a molecular weight of 475.95 and a molecular formula of C21H22ClN5O4S. Its chemical name is 3-(4-chlorobenzenesulfonyl)-N,N-diethyl-7,8-dimethoxy-[1,2,3]triazolo[1,5-a]quinazolin-5-amine. The compound is soluble in DMSO at 33.33 mg/mL. It is a solid powder with a purity of ≥98%. It is typically stored in dry, dark conditions at -20°C.
|
| Toxicity/Toxicokinetics |
Targocil exhibits low toxicity for human corneal epithelial cells at 5 μg/mL, even after 24 hours of exposure. However, at 40 μg/mL, it shows toxicity at all time points tested. The compound's safety profile requires further evaluation in vivo. Standard safety precautions should be taken when handling this compound.
|
| References |
[1]. Suzuki T, et al. In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Feb;55(2):767-74
|
| Additional Infomation |
Targocil is a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis with activity against MSSA and MRSA (MIC90 = 2 μg/mL for both). It is a synthetic compound with potential therapeutic applications against drug-resistant bacterial infections. Targocil is a derivative of 1835F03 and shows better activity against keratitis isolates. It is a research compound not approved for clinical use.
|
| Molecular Formula |
C21H22CLN5O4S
|
|---|---|
| Molecular Weight |
475.948
|
| Exact Mass |
475.108
|
| Elemental Analysis |
C, 53.00; H, 4.66; Cl, 7.45; N, 14.71; O, 13.45; S, 6.74
|
| CAS # |
1200443-21-5
|
| Related CAS # |
1200443-21-5
|
| PubChem CID |
44547009
|
| Appearance |
Solid powder
|
| LogP |
4.707
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
728
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])S(C1=C2N=C(C3=C([H])C(=C(C([H])=C3N2N=N1)OC([H])([H])[H])OC([H])([H])[H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])(=O)=O
|
| InChi Key |
TYNZGYMGTTUYKZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22ClN5O4S/c1-5-26(6-2)19-15-11-17(30-3)18(31-4)12-16(15)27-20(23-19)21(24-25-27)32(28,29)14-9-7-13(22)8-10-14/h7-12H,5-6H2,1-4H3
|
| Chemical Name |
3-(4-Chlorophenylsulfonyl)-N,N-diethyl-7,8-dimethoxy-[1,2,3]triazolo[1,5-a]quinazolin-5-amine
|
| Synonyms |
QC-993; QC 993; QC993; Targocil;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~70.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: 10% DMSO+90% Corn Oil: ≥ 2.5 mg/mL (5.25 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1011 mL | 10.5053 mL | 21.0106 mL | |
| 5 mM | 0.4202 mL | 2.1011 mL | 4.2021 mL | |
| 10 mM | 0.2101 mL | 1.0505 mL | 2.1011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA